HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement, Drug Co-Packaging Potential Could Be Clipped In FDA Proposed Rule

This article was originally published in The Rose Sheet

Executive Summary

Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN encourages FDA to allow. FDA will determine on a case-by-case basis whether co-packaged OTCs and supplements already available are in violation of a proposed rule on drug co-packaging.

Advertisement

Related Content

Innovus Stretches Strongest Footprint With Boston Topicals Brands Deal
Supplements More 'Mainstream' Than Alternative In Consumer Health Market
Tech Transfer Roundup: Janssen, Eisai, Apexian, Innovus And More
Fluticasone Spray Competition Grows With Perrigo Launch Of West-Ward Product
Industry Roundup: Supplement Labeling Guide Corrected, Nu Skin Settles
Bayer Warning Letters Reinforce FDA Ban On Supplement/Drug Combinations

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS121156

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel